Article
In Vivo Study of Newly Developed Albumin-Conjugated Urate Oxidase for Gout Treatment
2023-10-24
Abstract excerpt
<h4>Background: </h4> Exogenously providing engineered Uox with enhanced half-life is one of the important urate-lowering treatments for gout. The potential of PAT101, a recombinant human albumin (rHA)-conjugated variant, was evaluated and compared as a novel gout treatment through various in vivo studies with PAT101 and competing drugs. <h4>Methods: </h4>: PAT101 was produced by site-specific conjugation of rHA...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 3a8822e1-9cd5-5a76-9547-0f015056fac3
- DOI
- 10.21203/rs.3.rs-3460642/v1
